AbCellera Biologics (NASDAQ:ABCL) versus Proteo (OTCMKTS:PTEO) Head to Head Analysis

Proteo (OTCMKTS:PTEO) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Insider & Institutional Ownership

61.4% of AbCellera Biologics shares are held by institutional investors. 32.5% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Proteo and AbCellera Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Proteo	N/A	N/A	N/A
AbCellera Biologics	-463.77%	-13.40%	-10.44%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Proteo and AbCellera Biologics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Proteo	0	0	0	0	N/A
AbCellera Biologics	0	1	5	0	2.83

AbCellera Biologics has a consensus target price of $14.20, suggesting a potential upside of 416.36%. Given AbCellera Biologics’ higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than Proteo.

Valuation and Earnings

This table compares Proteo and AbCellera Biologics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Proteo	N/A	N/A	N/A	N/A	N/A
AbCellera Biologics	$33.05 million	24.46	-$146.40 million	($0.52)	-5.29

Proteo has higher earnings, but lower revenue than AbCellera Biologics.

Summary

AbCellera Biologics beats Proteo on 5 of the 8 factors compared between the two stocks.

About Proteo

Proteo, Inc., a clinical stage drug development company, intends to develop, promote, and market pharmaceuticals and other biotech products. The company focuses on the development of pharmaceuticals based on Elafin, a human protein that naturally occurs in human skin, lungs, and mammary glands for use in the treatment of post-surgery damage to tissue; complications resulting from organ transplantation; pulmonary hypertension; and injuries caused by accidents, cardiac infarction, and other diseases. It has a license and collaboration agreement with ARTES Biotechnology GmbH to produce Elafin by using the sublicensed yeast HANSENULA POLYMORPHA. The company was founded in 1992 and is based in Irvine, California.

About AbCellera Biologics

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.